Recent News

• 04.17.2025 - Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
• 12.20.2024 - Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine
• 12.18.2024 - Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
• 12.18.2024 - Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
• 11.21.2024 - Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates

Recent Filings

• 04.17.2025 - EX-99.1 EX-99.1
• 04.17.2025 - 8-K Current report
• 04.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.03.2025 - 8-K Current report
• 02.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.15.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 12.19.2024 - EFFECT Notice of Effectiveness
• 12.11.2024 - CORRESP Correspondence